Essential Thrombocythemia (ET)
Oncology·MeSH: Bone Marrow Neoplasms
Prevalence
30.0 / 100K
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Preclinical(1)
| Drug | Company |
|---|---|
| dmr-001 | Damora Therapeutics, Inc. (DMRA) |
Frequently asked questions
How many drugs are in development for Essential Thrombocythemia (ET)?
BioSniper tracks 1 drug in development for Essential Thrombocythemia (ET) across 1 company.
How many clinical trials target Essential Thrombocythemia (ET)?
There are 1 clinical trial targeting Essential Thrombocythemia (ET) tracked by BioSniper.
What is the prevalence of Essential Thrombocythemia (ET)?
The estimated prevalence of Essential Thrombocythemia (ET) is approximately 30.0 per 100,000 population.
Deep-dive into Essential Thrombocythemia (ET)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis